Quest Diagnostics Management
Management criteria checks 4/4
Quest Diagnostics' CEO is Jim Davis, appointed in Nov 2022, has a tenure of 2.25 years. total yearly compensation is $12.67M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.067% of the company’s shares, worth $12.63M. The average tenure of the management team and the board of directors is 2.6 years and 5.5 years respectively.
Key information
Jim Davis
Chief executive officer
US$12.7m
Total compensation
| CEO salary percentage | 9.3% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.07% |
| Management average tenure | 2.6yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Quest Diagnostics Incorporated (NYSE:DGX) Yearly Results: Here's What Analysts Are Forecasting For This Year
Feb 02
Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation
Jan 28Quest Diagnostics Incorporated (NYSE:DGX) Could Be Riskier Than It Looks
Jan 26Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Dec 18Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?
Nov 30Investors Met With Slowing Returns on Capital At Quest Diagnostics (NYSE:DGX)
Nov 12Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E
Oct 23Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Oct 15These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Quest Diagnostics: Moving Past Covid
Oct 25Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | US$866m |
| Sep 30 2024 | n/a | n/a | US$838m |
| Jun 30 2024 | n/a | n/a | US$836m |
| Mar 31 2024 | n/a | n/a | US$842m |
| Dec 31 2023 | US$13m | US$1m | US$850m |
| Sep 30 2023 | n/a | n/a | US$759m |
| Jun 30 2023 | n/a | n/a | US$790m |
| Mar 31 2023 | n/a | n/a | US$789m |
| Dec 31 2022 | US$12m | US$806k | US$942m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$4m | US$625k | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$4m | US$577k | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | US$749m |
| Mar 31 2020 | n/a | n/a | US$771m |
| Dec 31 2019 | US$3m | US$590k | US$835m |
| Sep 30 2019 | n/a | n/a | US$709m |
| Jun 30 2019 | n/a | n/a | US$707m |
| Mar 31 2019 | n/a | n/a | US$720m |
| Dec 31 2018 | US$3m | US$590k | US$733m |
Compensation vs Market: Jim's total compensation ($USD12.67M) is about average for companies of similar size in the US market ($USD12.51M).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Davis (61 yo)
2.3yrs
Tenure
US$12,673,834
Compensation
Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 2.3yrs | US$12.67m | 0.067% $ 12.6m | |
| Executive VP & CFO | 2.6yrs | US$3.98m | 0.016% $ 3.0m | |
| Senior VP & General Counsel | 25.5yrs | US$2.25m | 0.040% $ 7.4m | |
| Executive Vice President of Regional Businesses | no data | US$3.16m | 0.066% $ 12.3m | |
| Senior Vice President of Clinical Solutions | 2.5yrs | US$2.02m | 0.011% $ 2.0m | |
| Senior VP | 5.8yrs | no data | 0.032% $ 6.0m | |
| Senior VP | less than a year | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Compliance Officer | 2.3yrs | no data | no data | |
| Senior VP and Chief Marketing & Communications Officer | no data | no data | no data | |
| Senior VP & Chief Human Resources Officer | 7yrs | no data | no data | |
| Senior Vice President of Strategy | 9yrs | no data | no data |
2.6yrs
Average Tenure
61yo
Average Age
Experienced Management: DGX's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 2.3yrs | US$12.67m | 0.067% $ 12.6m | |
| Independent Director | 11.1yrs | US$315.44k | 0.023% $ 4.2m | |
| Director | less than a year | no data | no data | |
| Lead Independent Director | 13.2yrs | US$345.94k | no data | |
| Independent Director | 20.2yrs | US$342.12k | no data | |
| Independent Director | 6yrs | US$312.33k | 0.0026% $ 483.3k | |
| Independent Director | 10.6yrs | US$315.73k | 0.015% $ 2.8m | |
| Independent Director | 4.9yrs | US$300.44k | no data | |
| Independent Director | 3.5yrs | US$300.44k | no data | |
| Independent Director | 1.8yrs | US$280.41k | no data |
5.5yrs
Average Tenure
65yo
Average Age
Experienced Board: DGX's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 09:10 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quest Diagnostics Incorporated is covered by 45 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Kemp Dolliver | Avondale Partners |
| Eric Coldwell | Baird |